36 results
8-K
EX-10.1
MIRA
Mira Pharmaceuticals Inc
28 Jun 24
Departure of Directors or Certain Officers
5:00pm
to, expand, continue and/or advance the Company’s Proprietary Assets or the potential manufacture, formulation, use, efficacy or safety thereof; and/or (ii
10-K
2023 FY
EX-4.4
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
or omission which was committed in bad faith or with malicious purpose or in a manner exhibiting wanton and willful disregard of human rights, safety
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
structured phases, starting with IND-enabling studies and progressing through Phase 1 and Phase 2 clinical trials. These trials aim to establish the safety … ), and potentially PTSD. The strategy underscores patient safety while evaluating Ketamir-2’s therapeutic benefits and risks. The successful development
8-K
MIRA
Mira Pharmaceuticals Inc
7 Mar 24
Other Events
4:45pm
”). No representations are made as to the safety or effectiveness of these product candidates for the uses for which they are being studied. There is no assurance
8-K
EX-10.1
auuet 6421
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
8-K
EX-99.1
st47k
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
10-Q
jhuqqybbtu6jydcc27f
15 Sep 23
Quarterly report
4:45pm
8-K
EX-1.1
n30rx ecdbw3u
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
424B4
6rwjjxzp
4 Aug 23
Prospectus supplement with pricing info
1:01pm
424B1
egongmntot0bsicmvr
4 Aug 23
Prospectus with pricing info
12:59pm
S-1
EX-10.9
1qtqqdg2lr8
29 Jun 23
IPO registration
4:39pm